- Potential benefitIncreases access to discounted outpatient drugs for rural patients served by rural emergency hospitals.
- Potential benefitLowers pharmacy acquisition costs for eligible REHs, potentially improving hospital financial margins.
- Potential benefitMay reduce out-of-pocket prescription costs for low-income rural patients served by these hospitals.
Rural 340B Access Act of 2025
Referred to the House Committee on Energy and Commerce.
This bill amends section 340B(a)(4) of the Public Health Service Act to add rural emergency hospitals to the definition of covered entities eligible for the 340B drug discount program. It specifies eligible ownership types: state or local government-owned, public or private non‑profit granted governmental powers, or private non‑profit with a contract to provide care to low‑income individuals not eligible for Medicare or Medicaid.
Liberals emphasize improved rural access and equity benefits
Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and accountability detail.
This bill amends section 340B(a)(4) of the Public Health Service Act to add rural emergency hospitals to the definition of covered entities eligible for the 340B drug discount program.
It specifies eligible ownership types: state or local government-owned, public or private non‑profit granted governmental powers, or private non‑profit with a contract to provide care to low‑income individuals not eligible for Medicare or Medicaid.
Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufacturers.
Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and accountability detail.
Liberals emphasize improved rural access and equity benefits
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- ManufacturersExpands manufacturer discounts, potentially shifting costs to other purchasers or contributing to higher list prices.
- ManufacturersMay increase administrative and compliance burden for HRSA, manufacturers, and participating hospitals.
- Potential burdenCould heighten program integrity risks like diversion or duplicate discounts absent strengthened oversight.
Why the argument around this bill splits.
Liberals emphasize improved rural access and equity benefits
Likely sees the bill as a targeted expansion of an existing program to strengthen rural health care capacity and lower drug costs for vulnerable patients.
Views it as consistent with improving access and equity for low‑income rural populations, though wants safeguards against misuse.
Generally supportive of expanding access to rural care but cautious about implementation details and budgetary effects.
Sees value in helping rural hospitals, but wants clear accountability, fiscal estimates, and guardrails against unintended incentives.
Mixed view: welcomes measures that preserve rural hospitals, but skeptical about expanding federal program eligibility and its downstream effects.
Concerned about expanding entitlements, regulatory complexity, and costs to private sector drug manufacturers.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufacturers.
- No official cost or CMS implementation estimate included
- Intensity of pharmaceutical industry lobbying and litigation threat
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberals emphasize improved rural access and equity benefits
Modest chance: technically simple and constituency-friendly, but expansion of 340B typically draws sustained opposition from drug manufactu…
Relative to its intended legislative type, this bill is a focused statutory amendment that is precise in its textual change and in how it references existing law, but it lacks broader implementation, fiscal, and account…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.